Advanced Prostate Cancer VL

Looking Into the Future: Oligometastatic Disease Presentation - Misha Beltran

Details
During the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) Himisha Beltran presented an overview looking into the future of oligometastatic disease, and where she predicts we will be in two years’ time. Her presentation focused on refined clinical definitions for disease stratification, nominated molecular biomarkers to capture biologic disease states and defined goals of care for impro...

Movember Session: Outcomes Research – IRONMAN Project - Alicia Morgans and Ian Davis

Details
Alicia Morgans and Ian Davis presented an update on the IRONMAN study, an International Registry for Men with Advanced Prostate Cancer at the Advanced Prostate Cancer Consensus Conference (APCCC). The ultimate goal of this project is to provide the most elaborate description and understanding of patients with advanced prostate cancer. The project includes a description of treatment changes, advers...

How to Treat Men with Newly Diagnosed cN1 cM0 Prostate Cancer: Surgery Options Presentation - Declan Murphy

Details
Declan Murphy presented on node-positive prostate cancer focusing on the staging of high-risk/locally advanced prostate cancer session on Node-positive Prostate Cancer (N1 but M0), How to Treat Men with Newly Diagnosed cN1 cM0 at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. He elaborates on the performance of conventional imaging for staging clinical node status and the evidence...

How to Treat Men With Newly Diagnosed cN1 cM0 Prostate Cancer - Systemic Therapy Options - Nicholas James

Details
Nick James presented on the systemic therapy options for men with node-positive hormone-sensitive prostate cancer (HSPC), including whether the primary tumor should be treated, and which treatments can be combined at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Also highlighted in his presentation is the role of docetaxel in M0 and M1 HSP, abiraterone’s role in high-risk M0 HSPC...

Management of Men With PSA Recurrence or Persistence After Prostatectomy: Presentation - Christopher Evans

Details
Christopher Evans, Professor and Chair, Department of Urologic Surgery at UC-Davis discussed the management of men with PSA recurrence or persistence after radical prostatectomy during the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 session on PSA recurrence after radical local therapy and oligometastatic prostate cancer. He followed Dr. Felix Feng's presentation on PSA Recurrence a...

Management of Men with PSA Recurrence After Radical Local Radiation Therapy Presentation - Felix Feng

Details
Felix Feng presented during the PSA Recurrence after Radical Local Therapy and Oligometastatic Prostate Cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). He focused on the topic of management of men with PSA recurrence after radical local radiation therapy. Of the 1.2 million-plus patients that are diagnosed with prostate cancer each year worldwide, in the United St...

Disparities in Prostate Cancer Management in the United States Presentation - Alicia Morgans

Details
At the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) Dr. Alicia Morgans presented on disparities in prostate cancer management in the United States. Dr. Morgans highlights the 174,650 new cases of prostate cancer in the United States in 2019 and noting that social health is determined by many factors which could be responsible for these disparities, she frames her discussion around wh...

Pharmaco-ethnicity and Its Impact on Treatment Presentation - Darren MC Poon

Details
At the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) Darren Poon gave an overview of prostate cancer in the East-Asian ethnicity. This ethnicity includes China, (including Hong-Kong and Macau), Japan, Mongolia, North Korea, South Korea, and Taiwan. When assessing the taxane related adverse events in Asian prostate cancer patients, compared to the rates described in the major studies,...

APCCC 2019 Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study - Charles Ryan

Details
Charles Ryan and Alicia Morgans encourage participation in a 6 minute (survey) study available on UroToday.com, titled the Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study , a questionnaire intended to determine the global consensus among all physicians treating patients with advanced prostate cancer. The aim is to further understand global patterns of care in advanc...

Clinical Utility of Molecular Biomarkers Presentation - Johann de Bono

Details
Professor de Bono presents the clinical utility of predictive molecular biomarkers in advanced prostate cancer during the first session of the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Biographies: Johann de Bono, MB ChB FRCP MSc Ph.D. FMedSci. Professor Johann de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cance...
email news signup